PP-A8620A-00

antibody from Novus Biologicals

Targeting: EHMT2 BAT8, C6orf30, Em:AF134726.3, G9A, KMT1C, NG36/G9a

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

PP-A8620A-00

Provider

Novus Biologicals

Product name

Mouse Monoclonal G9a/EHMT2 Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from ascites. This antibody specifically recognizes mouse G9a and cross-reacts with human G9a. Not yet tested in other species.

Reactivity

Human, Mouse

Host

Mouse

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 ug

Storage

This antibody is stable for greater than six months when held at -20degrees C in a manual defrost freezer or at -70degreesC. Upon thawing, the antibody can be stored at 2degrees - 8degrees C for at least 1 month without detectable loss of activity. Avoid repeated freeze-thaw cycles.

References

Submitted references

Cyclin D1 integrates G9a-mediated histone methylation.

Li Z, Jiao X, Di Sante G, Ertel A, Casimiro MC, Wang M, Katiyar S, Ju X, Klopfenstein DV, Tozeren A, Dampier W, Chepelev I, Jeltsch A, Pestell RG
Oncogene 2019 May;38(22):4232-4249

---

Mutual inhibition between HDAC9 and miR-17 regulates osteogenesis of human periodontal ligament stem cells in inflammatory conditions.

Li L, Liu W, Wang H, Yang Q, Zhang L, Jin F, Jin Y
Cell death & disease 2018 May 1;9(5):480

---

Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.

Chen RJ, Shun CT, Yen ML, Chou CH, Lin MC
Oncotarget 2017 Sep 22;8(37):62081-62098

---

Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma.

Liu CW, Hua KT, Li KC, Kao HF, Hong RL, Ko JY, Hsiao M, Kuo ML, Tan CT
Molecular cancer therapeutics 2017 Jul;16(7):1421-1434

---

Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.

Li KC, Hua KT, Lin YS, Su CY, Ko JY, Hsiao M, Kuo ML, Tan CT
Molecular cancer 2014 Jul 15;13:172

---

The methyltransferase G9a regulates HoxA9-dependent transcription in AML.

Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L, Zhang R, Krosl J, Yung E, Kirschner J, Rosten P, Underhill TM, Jin J, Hébert J, Sauvageau G, Humphries RK, Rossi FM
Genes & development 2014 Feb 15;28(4):317-27

---

H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.

Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, Lai TC, Chang JS, Jan YH, Chien MH, Yang CJ, Huang MS, Hsiao M, Kuo ML
Cancer research 2010 Oct 15;70(20):7830-40

---

DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity.

Dong KB, Maksakova IA, Mohn F, Leung D, Appanah R, Lee S, Yang HW, Lam LL, Mager DL, Schübeler D, Tachibana M, Shinkai Y, Lorincz MC
The EMBO journal 2008 Oct 22;27(20):2691-701